

Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect

Joan Albanell, Jose Baselga

Trastuzumab (Herceptin) is a humanized antibody directed against the extracellular domain of the tyrosine kinase receptor HER2 that has shown clinical activity against HER2-overexpressing breast tumors (1-4). HER2, the targeted receptor, is a member of the epidermal growth factor (EGF) receptor family of receptors, also known as the type I receptor tyrosine kinase family [for review, see (5)]. HER2 is overexpressed in 25%-30% of breast cancers, and its overexpression is associated with a high risk of relapse and death (6). In this group of tumors with unfavorable prognosis, trastuzumab has been a valuable addition to standard therapy, with the pivotal studies demonstrating a clear survival benefit (2,3). However, even in the selected group of patients with very high levels of HER2 overexpression who derive the greatest benefit from trastuzumab therapy, the response rate from this highly specific, targeted agent is limited in magnitude and duration (7).

Lu et al. (21) appropriately propose that strategies that target IGF-IR signaling may prevent or delay development of resistance to trastuzumab. A link between IGF-IR signaling in the modulation of response to monoclonal antibodies has been shown also for the EGF receptor, which is closely related to HER2. In this regard, a recent study (26) has shown that IGF-I signaling temporarily prevented the apoptosis mediated by the anti-EGF receptor monoclonal antibody C225 in the EGF receptor auxotroph cell line DiFi. It is interesting that such inhibition was sensitive to an inhibitor of the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway (26). Because the PI-3K/Akt pathway is poorly suppressed by trastuzumab in breast cancer (16), it is tempting to speculate that this pathway may play an important role in the observations by Lu et al. (21).

What are the molecular signaling events underlying the interference of IGF-IR signaling in trastuzumab response? Lu et al. (21) characterized opposing effects of trastuzumab and IGF-IR on p27^{Kip1}. The induction of p27^{Kip1} by anti-HER2 antibodies contributes to their effects on growth inhibition (6). However, in SKBR3/IGF-IR cells, the baseline levels of p27 were very low compared with those in SKBR3/neo control cells, and trastuzumab could not induce p27^{Kip1} expression. This ef-945e8664.3834 -1.15 T2(eftr09)-43mighftro9mediato9interfereno9bet

HER29. i29.signalin29.patslin29.tha29.p27

- growth factors and their receptors in breast cancer. *Breast Cancer Res* 2000;22:170–5.
- (23) Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor (27) signaling pathways in mammary gland by pure antiestrogen ICI 182,780. *Clin Cancer Res* 2001;7:2545–54.
- (24) Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin- (28) like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. *Cancer Res* 2001;61:6747–54.
- (25) Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of (29) breast cancer. *Lancet* 1998;351:1393–6.
- (26) Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. *Oncogene* 2001;20:1913–22.
- Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. *Mol Cell Biol* 1999;19:7203–15.
- Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. *Mol Carcinog* 1996;15:227–38.
- Balana ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, et al. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. *Oncogene* 2001;19:34–47.